Prademagene zamikeracel (pz-cel) could be a new treatment for rare genetic disease recessive dystrophic epidermolysis bullosa (RDEB).
Abeona Therapeutics Inc. has resubmitted its biologics license application (BLA) to the FDA for prademagene zamikeracel (pz-cel), a gene therapy targeting recessive dystrophic epidermolysis bullosa (RDEB), according to a news release published today.
The resubmission, informed by a Type A meeting with the FDA in August 2024, addresses the Chemistry, Manufacturing and Controls (CMC) requirements outlined in the FDA's complete response letter issued in April. The letter highlighted additional CMC information necessary for approval but did not identify any deficiencies in clinical efficacy or safety. Consequently, no new clinical trials or data were requested for the resubmission, which includes findings from the Phase 3 VIITAL™ study and a Phase 1/2a study.
Vish Seshadri, CEO of Abeona, expressed optimism about the resubmission, stating, “We have worked closely with the FDA in preparing for the pz-cel BLA resubmission and thank the Agency for their ongoing guidance.” Seshadri emphasized Abeona’s confidence in the revised submission, which aims to meet all FDA requirements.
Upon acceptance, the FDA is expected to establish a new Prescription Drug User Fee Act (PDUFA) target action date for pz-cel, with a review period of two to six months.
RDEB is a rare genetic condition characterized by fragile skin that blisters and wounds easily due to a lack of collagen VII, a critical protein for skin integrity. It is caused by a defect in the COL7A1 gene. Patients can suffer for years before finding treatment and are at an increased risk for infection and squamous cell carcinoma. Pz-cel is made from a patient's own genetically corrected skin cells.
The FDA’s acceptance decision after a BLA resubmission is typically made within 14 days of resubmission.
The Centers for Medicare and Medicaid Services granted a product specific approval code for pz-cel in August.
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More
ICER Gives Cell Therapy for Post-Transplant Complications High Rating
Published: October 31st 2024 | Updated: October 31st 2024ICER has given tabelecleucel a rating of A, indicating the T cell therapy for Epstein-Barr virus related post-transplant lymphoproliferative disease has a high certainty of substantial net health benefit and would be cost-effective if priced between $143,900 and $273,700.
Read More